Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Alexion Pharmaceuticals Inc. ALXN

Healthcare Biotechnology
Alexion Pharmaceuticals specializes in developing and marketing drugs for rare, life-threatening medical conditions. Its blockbuster product, Soliris, is approved for paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). Next-generation Ultomiris is approved in PNH and aHUS... see more

Recent & Breaking News (NDAQ:ALXN)

Alexion to Present at Upcoming Investor Conferences

Business Wire February 29, 2016

Alexion Employees Across the Globe Join Together to Support Rare Disease Day 2016

Business Wire February 29, 2016

Pan Canadian Pharmaceutical Alliance Says Ended Negotiations With Alexion for Listing of Soliris for Treatment of Atypical Hemolytic Uremic Syndrome -Reuters

Press Releases February 16, 2016

Hilliard Lyons Upgrades Activision Blizzard to Buy

Press Releases February 16, 2016

Alexion to Present at the Leerink Partners 5th Annual Global Healthcare Conference

Business Wire February 4, 2016

Alexion Reports Fourth Quarter and Full Year 2015 Results and Provides Financial Guidance for 2016

Business Wire February 3, 2016

Alexion Pharmaceuticals to Report Fourth Quarter and Full Year 2015 Results on Wednesday, February 3, 2016

Business Wire January 20, 2016

Researchers to Present New Data at ENDO 2016 Advancing the Understanding of Strensiq® (asfotase alfa) in Infants, Children and Adult Patients with Hypophosphatasia (HPP)

Business Wire January 15, 2016

Alexion to Present at the 34th Annual J.P. Morgan Healthcare Conference

Business Wire January 4, 2016

Alexion Highlights Innovative Rare Disease Portfolio at Investor Day Meeting

Business Wire December 10, 2015

Alexion to Highlight Innovative Rare Disease Portfolio at Investor Day Meeting

Business Wire December 10, 2015

FDA Approves Kanuma(TM) (sebelipase alfa) for the Treatment of Patients with Lysosomal Acid Lipase Deficiency (LAL-D)

Business Wire December 8, 2015

How it All Plays Out - Research on LinkedIn, Micron Technology, Alexion Pharmaceuticals and Fitbit

Accesswire December 8, 2015

Data from the International Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry Presented at ASH Annual Meeting Underscore Devastating Nature of PNH and Benefits of Soliris® (eculizumab) Treatment

Business Wire December 7, 2015

Alexion to Highlight Robust Rare Disease Pipeline at Investor Day

Business Wire November 19, 2015

Long-Term Follow-up Study Presented at ASN 2015 Supports Effectiveness of Soliris® (eculizumab) in Preventing Thrombotic Microangiopathy (TMA) Events in Patients with Atypical Hemolytic Uremic Syndrome (aHUS)

Business Wire November 7, 2015

Researchers to Present Data on Enhancing the Understanding of PNH and aHUS and Underscoring the Effectiveness of Soliris® (eculizumab) Treatment at ASH 2015 Annual Meeting

Business Wire November 5, 2015

Alexion Reports Third Quarter 2015 Results

Business Wire October 29, 2015

Biotech ETFs: Buy, Buy, Buy?

Benzinga.com  October 27, 2015

FDA Approves Strensiq(TM) (asfotase alfa) for Treatment of Patients with Perinatal-, Infantile- and Juvenile-Onset Hypophosphatasia (HPP)

Business Wire October 23, 2015